# Risk of Cardiovascular Effects with Azithromycin

# RAMACHANDRAN KUMARESAN<sup>1</sup>, SUBISH PALAIAN<sup>2</sup>, SANTOSH THAPA<sup>3</sup>, PATHIYIL RAVI SHANKAR<sup>4</sup>

# Keywords: Arrhythmogenic, Macrolides, Prolonged QT intervals

## Dear Editor,

Pharmacology Section

Macrolides, a class of antibiotics produced by strains of *streptomyces* have a complex chemical structure being linked to one or more sugars (cladinasone and desosamine) and act by inhibiting protein synthesis [1]. Most commonly used macrolides are azithromycin, erythromycin, clarithromycin, and roxithromycin. The most common adverse effects of macrolides are diarrhea, abdominal pain, vomiting, severe skin reactions and other gastrointestinal problems [2].

Previously, azithromycin has been reported to be a broad spectrum macrolide antibiotic free from cardiac toxicity [3]. It is the first macrolide antibiotic belonging to the azalide group derived from erythromycin by adding a nitrogen atom to the lactone ring [4]. Azithromycin differs from other antibiotics in its unusual pharmacokinetic properties. It is rapidly accumulated in cells and tissues, particularly in blood leucocytes and is slowly released from the sites with a half life of 40h [5].

In the recent past azithromycin has been shown to possess proarrhythmic effects [6]. There are seven reports of QT interval prolongation in patients with normal QT intervals prescribed a five day course of azithromycin [5]. A recent article mentions that compared to other antibiotics like amoxicillin, ciprofloxacin and levofloxacin, the risk of cardiovascular death is more with azithromycin [7]. The United States Food and Drug Administration (US FDA) warns that azithromycin may cause abnormal changes in the heart's electrical activity leading to fatal arrhythmias [8]. This communication is based on the findings of a study [7] by medical researchers as well as another study reported by one of the manufacturers of azithromycin that assessed the arrhythmogenic potential for the drug [8]. This applies only to patients with prolonged QT intervals, low levels of blood potassium or magnesium, and a slower heart rate than normal. The possible mechanism of macrolide induced QT prolongation is inhibition of repolarization of cardiac cells through potassium channels [9,10]. The macrolide antibiotics erythromycin, clarithromycin and azithromycin show similar QT prolongation but have divergent proarrhythmic potential [11]. Administration of azithromycin to healthy human subjects resulted in acute stimulation of neutrophil degranulation and phagocytosis associated respiratory burst [12]. Patients with prolonged QT intervals need to obtain advice

from their healthcare professional before starting treatment with azithromycin. Health care professionals need to have information about their patient's family history, QT intervals, abnormal heart beat, and bradyarrhythmias before starting treatment with azithromycin.

The evidence shows that azithromycin not only produces cardiac arrest in patients with prolonged QT interval, but also affects healthy human subjects when azithromycin is taken for more than 4 days. If treatment is required for a longer duration, it is better to use other antibiotics like amoxicillin or ciprofloxacin. Azithromycin should be a priority candidate for pharmacovigilance and adverse drug reaction monitoring. In addition, large scale studies (if possible multicentric) covering large populations are needed to evaluate the exact clinical impact of these preliminary findings considering the large scale use of azithromycin and other macrolides.

# REFERENCES

- Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 1993;31 Suppl C: 1-9.
- Baselt RC. Disposition of toxic drugs and chemicals in man. 9<sup>th</sup> ed. USA: Biomedical Publications; 2011.
- [3] Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogen. *Clin Infect Dis.* 1998;27(1):28-32.
- [4] Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed. 2006;77(1):30-32.
- [5] Zuckerman JM. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am. 2000;14:449-62.
- [6] Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. NZ Med J. 2003;116:U666.
- [7] Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20):1881-90.
- [8] FDA Drug Safety Communication: Azithromycin and the risk of potentially fatal heart rhythms. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/ UCM343347.pdf (Accessed on 3rd September 2014).
- [9] Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther. 2002;302(1):320-27.
- [10] Miranda DG, McMain CL, Smith AJ. Medication-induced QT-Interval prolongation and torsades de pointes. US Pharm. 2011;36 (2):HS-2-8.
- [11] Peter M, Lars E, Hans JB, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218–25.
- [12] Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. *Eur J Pharmacol.* 2002; 450(3):277-89.

### PARTICULARS OF CONTRIBUTORS:

- 1. Tutor, Department of Pharmacology / Hospital and Clinical Pharmacy, College of Medical Sciences, Bharatpur, Chitwan, Nepal.
- 2. Associate Professor, Department of Pharmacology/Hospital and Clinical Pharmacy, College of Medical Sciences, Bharatpur, Chitwan, Nepal.
- 3. Tutor, Department of Pharmacology / Hospital and Clinical Pharmacy, College of Medical Sciences, Bharatpur, Chitwan, Nepal.
- 4. Professor, Department of Pharmacology, Xavier University School of Medicine, Aruba, Dutch Caribbean.

#### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Ramachandran Kumaresan.

Tutor and Hospital and Clinical Pharmacist, Department of Pharmacology / Hospital Pharmacy and Clinical Pharmacy, College of Medical Sciences, P.O Box. 23, Bharatpur, Chitwan, Nepal. E-mail : rcrama911@gmail.com

Date of Submission: Sep 03, 2014 Date of Peer Review: Oct 16, 2014 Date of Acceptance: Oct 22, 2014 Date of Publishing: Jan 01, 2015

FINANCIAL OR OTHER COMPETING INTERESTS: None.